jrnls.org logo
Submit

BROWSE ALL JOURNALS

SEE ALL 19 JOURNALS
International Journal of Pharmaceutical InvestigationNOW IN
Article

In vitro Anti-cancer Activity of Nandhi mezhugu (NM) in Ovarian Cancer Cell Line (PA-1) Using MTT Assay

Glara Anest Francis1, Sureka Arumugam1, Sabari Girija Navaneetha Krishnan1★, Ramamurthy Murugan2, Christian Gnanaraj Johnson2, Moses Erin Johnson Christian3, Meenakumari Ramasamy1★ Corresponding author

  1. 1National Institute of Siddha, Tambaram Sanatorium, Chennai, Tamilnadu, INDIA.
  2. 2Department of Noinadal, National Institute of Siddha, Tambaram Sanatorium, Chennai, Tamilnadu, INDIA.
  3. 3Caucasus International University, Tbilisi, GEORGIA.

CORRESPONDENCE

Sabari Girija Navaneetha Krishnan

National Institute of Siddha, Tambaram Sanatorium, Chennai, Tamilnadu, INDIA.

drgirijakrish@gmail.com

Received: 21-02-2023; Revised: 23-03-2023; Accepted: 20-04-2023.

Volume 13, Issue 3 · pp. 646–650 · PUBLISHED · DOI: 10.5530/ijpi.13.3.080

View on IJPI original site ↗

ABSTRACT

Introduction: Ovarian cancer is the fifth most common cause of cancer which causes more deaths than any other cancer of the female reproductive system because there is no effective screening and most women are diagnosed at advanced stages. The probability of survival at 5 years is less than 30%, and the limitation is that it will not respond to chemotherapy protocol and surgery as well. Nandhi mezhugu is a Siddha herbo-mineral drug widely used to treat cancer. Hence, the present study was intended to evaluate the anti-cancer activity of Nandhi mezhugu on (PA-1) cell line through MTT assay.Materials and Methods:Stock solutions were prepared from the formulation at various concentrations with serial dilution. Compared with the control and Methotrexate, the extracts were tested using MTT assay at different concentrations. Results:This study substantiated that the percentage of cell viability of cell line viability decrease with increase in concentration of the test drug NM. Least viability of cell was observed at the concentration of 200µg/mL was 73.02 ± 4.584%, followed by this at 100 µg and 50 µg shows 82.36 ± 3.084%, 87.81 ± 2.657, similarly 10 µg/mL shows 95.89 ± 1.054% cell viability in MTT assay. Conclusion:Thus, the current study brings forth scientific evidence for the efficacy of Nandhi mezhugu against the ovarian cancer (PA1) cell line.

KEYWORDS

Open in new tab

REFERENCES

As published

Showing references and in-text citations exactly as published.

    Cite this article

    SELECT FORMAT

    Francis, G. A., Arumugam, S., Krishnan, S. G. N., Murugan, R., Johnson, C. G., Christian, M. E. J., & Ramasamy, M. (). In vitro Anti-cancer Activity of Nandhi mezhugu (NM) in Ovarian Cancer Cell Line (PA-1) Using MTT Assay. International Journal of Pharmaceutical Investigation, 13(3), 646–650. https://doi.org/10.5530/ijpi.13.3.080